Orazio Taglialatela-Scafati

Prof. Orazio Taglialatela-Scafati

Department of Pharmacy, University of Naples “Federico II”, Via Domenico Montesano 49, 80131 Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2013 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AMAlejandro M. Mayer
Alejandro M. Mayer
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
NFNobuhiro Fusetani
Nobuhiro Fusetani
The peer-reviewed marine pharmacology literature from 2009 to 2011 is presented in this review, following the format used in the 1998–2008 reviews of this series. The pharmacology of structurally-characterized compounds isolated from marine animals, algae, fungi and bacteria is discussed in a comprehensive manner. Antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral pharmacological activities were reported for 102 marine natural products. Additionally, 60 marine compounds were observed to affect the immune and nervous system as well as possess antidiabetic and anti-inflammatory effects. Finally, 68 marine metabolites were shown to interact with a variety of receptors and molecular targets, and thus will probably contribute to multiple pharmacological classes upon further mechanism of action studies. Marine pharmacology during 2009–2011 remained a global enterprise, with researchers from 35 countries, and the United States, contributing to the preclinical pharmacology of 262 marine compounds which are part of the preclinical pharmaceutical pipeline. Continued pharmacological research with marine natural products will contribute to enhance the marine pharmaceutical clinical pipeline, which in 2013 consisted of 17 marine natural products, analogs or derivatives targeting a limited number of disease categories.

1 July 2017 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
DRDaniela Rigano
Daniela Rigano
CSCarmina Sirignano
Carmina Sirignano
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
Peroxisome proliferator activated receptors (PPARs) α, -γ and -β/δ are ligand-activated transcription factors and members of the superfamily of nuclear hormone receptor. These receptors play key roles in maintaining glucose and lipid homeostasis by modulating gene expression. PPARs constitute a recognized druggable target and indeed several classes of drugs used in the treatment of metabolic disease symptoms, such as dyslipidemia (fibrates, e.g. fenofibrate and gemfibrozil) and diabetes (thiazolidinediones, e.g. rosiglitazone and pioglitazone) are ligands for the various PPAR isoforms. More precisely, antidiabetic thiazolidinediones act on PPARγ, while PPARα is the main molecular target of antidyslipidemic fibrates. Over the past few years, our understanding of the mechanism underlying the PPAR modulation of gene expression has greatly increased. This review presents a survey on terrestrial and marine natural products modulating the PPARα system with the objective of highlighting how the incredible chemodiversity of natural products can provide innovative leads for this "hot" target.

13 July 2018 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
JMJames B. McAlpine
James B. McAlpine
SCShao-Nong Chen
Shao-Nong Chen
AKAndrei G. Kutateladze
Andrei G. Kutateladze
JMJohn B MacMillan
John B MacMillan
Giovanni AppendinoGiovanni Appendino
Giovanni Appendino
GPGuido F. Pauli
Guido F. Pauli
With contributions from the global natural product (NP) research community, and continuing the Raw Data Initiative, this review collects a comprehensive demonstration of the immense scientific value of disseminating raw nuclear magnetic resonance (NMR) data, independently of, and in parallel with, classical publishing outlets.

4 December 2013 in Molecules
Verified
Journal Article
Open access
PDF file
EFEnrica De Falco
Enrica De Falco
EMEmilia Mancini
Emilia Mancini
GRGraziana Roscigno
Graziana Roscigno
EMEnrico Mignola
Enrico Mignola
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
FSFelice Senatore
Felice Senatore
This research was aimed at investigating the essential oil production, chemical composition and biological activity of a crop of pink flowered oregano (Origanum vulgare L. subsp. vulgare L.) under different spatial distribution of the plants (single and binate rows). This plant factor was shown to affect its growth, soil covering, fresh biomass, essential oil amount and composition. In particular, the essential oil percentage was higher for the binate row treatment at the full bloom. The chemical composition of the oils obtained by hydrodistillation was fully characterized by GC and GC-MS. The oil from plants grown in single rows was rich in sabinene, while plants grown in double rows were richer in ocimenes. The essential oils showed antimicrobial action, mainly against Gram-positive pathogens and particularly Bacillus cereus and B. subtilis.

29 August 2017 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AMAlejandro M. Mayer
Alejandro M. Mayer
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
NFNobuhiro Fusetani
Nobuhiro Fusetani
The peer-reviewed marine pharmacology literature from 2012 to 2013 was systematically reviewed, consistent with the 1998–2011 reviews of this series. Marine pharmacology research from 2012 to 2013, conducted by scientists from 42 countries in addition to the United States, reported findings on the preclinical pharmacology of 257 marine compounds. The preclinical pharmacology of compounds isolated from marine organisms revealed antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral and anthelmitic pharmacological activities for 113 marine natural products. In addition, 75 marine compounds were reported to have antidiabetic and anti-inflammatory activities and affect the immune and nervous system. Finally, 69 marine compounds were shown to display miscellaneous mechanisms of action which could contribute to novel pharmacological classes. Thus, in 2012–2013, the preclinical marine natural product pharmacology pipeline provided novel pharmacology and lead compounds to the clinical marine pharmaceutical pipeline, and contributed significantly to potentially novel therapeutic approaches to several global disease categories.

14 July 2010 in Marine Drugs
Verified
Journal Article
Open access
PDF file
FSFernando Scala
Fernando Scala
EFErnesto Fattorusso
Ernesto Fattorusso
Marialuisa MennaMarialuisa Menna
Marialuisa Menna
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
MTMichelle Tierney
Michelle Tierney
DTDeniz Tasdemir
Deniz Tasdemir
In the present study,13 bromopyrrole alkaloids, including the oroidin analogs hymenidin (2), dispacamide B (3) and dispacamide D (4), stevensine (5) and spongiacidin B (6), their derivatives lacking the imidazole ring bromoaldisin (7), longamide B (8) and longamide A (9), the dimeric oroidin derivatives sceptrin (10) and dibromopalau’amine (11), and the non-oroidin bromopyrrolohomoarginin (12), manzacidin A (13), and agelongine (14), obtained from marine sponges belonging to Axinella and Agelas generahave been screened in vitro against four parasitic protozoa, i.e., two Trypanosoma species (T. brucei rhodesiense and T. cruzi), Leishmania donovani and Plasmodium falciparum (K1 strain, a chloroquine resistant strain), responsible of human diseases with high morbidity and, in the case of malaria, high mortality. Our results indicate longamide B (8) and dibromopalau’amine (11) to be promising trypanocidal and antileishmanial agents, while dispacamide B (3) and spongiacidin B (6) emerge as antimalarial lead compounds.In addition,evaluation of the activity of the test alkaloids (2–14) against three different enzymes (PfFabI, PfFabG, PfFabZ) involved in the de novo fatty acid biosynthesis pathway of P. falciparum (PfFAS-II) identified bromopyrrolohomoarginin (12) as a potent inhibitor of PfFabZ. The structural similarity within the series of tested molecules allowed us to draw some preliminary structure-activity relationships. Tests against the mammalian L6 cells revealed important clues on therapeutic index of the metabolites. This is the first detailed study on the antiprotozoal potential of marine bromopyrrole alkaloids.